Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1 3Phase 1/2 1

Status

Completed 39Terminated 15Withdrawn 7Active not recruiting 7Recruiting 5Unknown 3Suspended 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1Dermatologic 1

Conditions

Solid Tumor 1Melanoma 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 51fludarabine 38Injections 32Gemcitabine 25Paclitaxel 24Cisplatin 22Radiotherapy 19toripalimab 18pembrolizumab 18Carboplatin 17Capecitabine 17Fluorouracil 15Oxaliplatin 14Nivolumab 14Docetaxel 12camrelizumab 11apatinib 11Temozolomide 11Immunotherapy, Adoptive 11Cetuximab 11Bevacizumab 10Irinotecan 9Drug Therapy 9sintilimab 8Etoposide 8aldesleukin 7Taxes 7Rituximab 7Radiosurgery 7Peripheral Blood Stem Cell Transplantation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Unknown × trametinib × Clear all
NCT04303403 2023-10-11

Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma

National Cancer Centre, Singapore

Phase 1 Unknown
48 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT04965220 2023-08-09

HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid Tumors

Shanghai Henlius Biotech

Phase 1 Unknown
220 enrolled
Other solid neoplasm

Solid Tumor

NCT03088176 2020-10-12

Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma

West Cancer Center

Phase 1 Unknown
4 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡